WeVote
Log In

Bill

Bill

A 7310

Requires certain health insurance policies to provide coverage for diagnostic testing for ovarian cancer

2025 Regular Session Introduced by Gary Pretlow

Bill A 7310 mandates health insurance coverage for ovarian cancer diagnostic tests, improving access for women and promoting early detection for better outcomes.

REFERRED TO INSURANCE
0
WeVote Research Nonpartisan
Bill Summary · A 7310

Summary of Bill A 7310

Purpose and Intent

Bill A 7310 aims to enhance healthcare access by requiring certain health insurance policies to provide coverage for diagnostic testing specifically for ovarian cancer. The intent of this legislation is to improve early detection and treatment options for ovarian cancer, which is often diagnosed at a late stage, leading to poorer health outcomes.

Key Provisions

  • Coverage Requirement: The bill mandates that health insurance policies cover diagnostic tests for ovarian cancer. This includes, but is not limited to, tests such as:

    • CA-125 blood tests
    • Transvaginal ultrasounds
    • Other medically necessary diagnostic procedures as determined by healthcare providers.

  • Policy Applicability: The requirement applies to a range of health insurance plans, ensuring that individuals with these policies have access to necessary diagnostic testing without prohibitive out-of-pocket costs.

Affected Parties

  • Patients: Women at risk for ovarian cancer or those experiencing symptoms will benefit from increased access to diagnostic testing, potentially leading to earlier detection and better treatment outcomes.
  • Healthcare Providers: Medical professionals will have the assurance that diagnostic tests will be covered, allowing them to recommend necessary procedures without financial concerns for their patients.
  • Insurance Companies: Health insurers will need to adjust their policies and coverage options to comply with the new requirements set forth by this bill.

Procedural Aspects

  • Introduced Date: The bill was introduced on March 25, 2025.
  • Current Status: As of the latest legislative action, the bill has been referred to the Insurance Committee for further consideration.

Related Legislation

Bill A 7310 is part of a broader legislative context, with several related bills from prior sessions, including:
- A 917
- A 4238
- A 3177
- A 2521
- A 4223
- A 1745
- A 3684
- A 1824
- A 4779

These related bills may address similar issues or provide additional context regarding health insurance coverage and cancer diagnostics.

Conclusion

Bill A 7310 represents a significant step towards improving healthcare access for women at risk of ovarian cancer. By mandating insurance coverage for diagnostic testing, the bill seeks to facilitate early detection and ultimately improve health outcomes for patients. The bill is currently under review by the Insurance Committee, and its progress will be closely monitored by stakeholders in the healthcare community.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.